Best Picks,An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025

The FDA peptide warning letters issued in September 2024 and continuing into 2025 highlight a critical period of regulatory scrutiny for companies involved in the marketing and distribution of peptide products. These warning letters serve as formal notifications from the FDA (Food and Drug Administration) to entities that have been found to be in violation of federal laws and regulations. Understanding the context and implications of these letters warning about unapproved or misbranded products is crucial for both consumers and industry stakeholders.

The recent surge in FDA warning letters specifically targeting peptides reflects the agency's increasing focus on ensuring the safety and efficacy of drugs and drug products available to the public. This intensified oversight is particularly relevant for compounds like semaglutide and tirzepatide, which have gained significant attention for their therapeutic applications, especially in weight management. For instance, USApeptide.com received a warning letter on March 11, 2025, for introducing unapproved and misbranded semaglutide and tirzepatide drug products into interstate commerce. This case exemplifies the FDA's commitment to preventing the illegal distribution of such substances.

The FDA's War on Peptides has been a continuous effort, with a notable wave of warning letters issued to online peptide vendors in September 2024. These actions targeted vendors selling products known to contain semaglutide, tirzepatide, and other GLP-1 products. More recently, on December 17, 2024, the FDA published five warning letters previously issued to makers of knockoff GLP-1 drugs, underscoring a persistent issue with counterfeit or substandard products entering the market.

The repercussions of these FDA warning letters can be far-reaching. Companies receiving such notifications are expected to take immediate corrective actions to rectify the violations. Failure to comply can lead to further enforcement actions, including seizures, injunctions, and civil or criminal penalties. The FDA's proactive stance aims to protect consumers from potentially harmful or ineffective products, especially when they are marketed with unverified claims or without proper regulatory approval.

Furthermore, the FDA has also issued warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products. On March 3, 2026, the FDA issued 30 such warning letters to telehealth firms, citing illegal marketing practices. This indicates that the FDA's scrutiny extends beyond manufacturers to encompass the entire supply chain and marketing channels, including direct-to-consumer programs. For example, An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025, highlighted issues related to a direct-to-consumer program, demonstrating the broad scope of the FDA's regulatory reach.

The FDA's actions in September 2025, including specific warning letters to entities like JulyMD and Novo Nordisk Inc. on September 9, 2025, further illustrate the agency's ongoing efforts to regulate the peptide market. These letters warning companies about promotional claims and product integrity are vital for maintaining public trust and safety. The FDA's reaffirmation of strict regulations amid GLP-1 drug developments, as announced on February 11, 2026, signifies a continued commitment to a focused approach in regulating the marketing of glucagon-likepeptide-1 (GLP-1) drugs.

In summary, the period surrounding September 2025 has been marked by significant FDA enforcement actions concerning peptides. The issuance of warning letters to various entities, including manufacturers, telehealth providers, and distributors, underscores the FDA's dedication to ensuring that peptide products meet stringent safety, efficacy, and marketing standards. Consumers seeking peptide treatments should exercise caution, verify the legitimacy of products and providers, and consult with healthcare professionals to ensure they are receiving safe and approved medical interventions. The FDA's comprehensive oversight, including FDA warning letters for GLP-1 related products, is an essential component of safeguarding public health.